| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb96d775a3d4dbafbaadf7f5ee209b58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
2005-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5ed3503de19e668f2c4b6eb0e7c19a1 |
| publicationDate |
2008-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7396524-B2 |
| titleOfInvention |
Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy |
| abstract |
Methods for screening compounds for their potential to induce or inhibit a cardiac arrhythmia are disclosed. The methods comprise determining the ratio of the time constant (τ) of I Ca,L recovery in tissue expressing the L-type calcium channel or any subunit or combination thereof of the L-type calcium channel treated with a test compound to the ventricular repolarization time of cardiac tissue treated with a test compound. The methods further comprise determining an arrhythmic risk score for a specified dose of a test compound. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11696902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11610660-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007089179-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7794951-B2 |
| priorityDate |
2005-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |